Search

Displaying results 2311 - 2320 of 10000 in total
  1. Target

    Interleukin-20

    go.drugbank.com/bio_entities/BE0020481
    TargetHumans

    Exert its effects via the type I IL-20 receptor complex consisting of IL20RA and IL20RB (PubMed:11706020). … Alternatively, can mediate its activity through a second receptor complex called type II IL-20 receptor complex composed of IL22RA1 and IL20RB (PubMed:11564763).

    Polypeptides: Interleukin-20Synonyms: IL-20
  2. Drug

    Teclozan

    go.drugbank.com/drugs/DB13205
    Investigational

    Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

    Products: TECLOZANTABLETAS 500 MG
  3. Drug

    1,3-Propanediol

    go.drugbank.com/drugs/DB02774
    Investigational

    Products: Second 20 Y-ZONE Serum
  4. Drug

    Selenium Sulfide

    go.drugbank.com/drugs/DB00971
    Approved

    Selenium Sulfide is an antifungal agent as well as a cytostatic agent, slowing the growth of hyperproliferative cells in seborrhea. … Selenium Sulfide is the active ingredient often used in shampoos for the treatment of dandruff, seborrheic dermatitis and tinea capitis, a fungal infection that is primarily a disease of preadolescent

    Products: Selsun Blue 2-in-1, Selsun Blue, 2-IN-1
  5. Drug

    Pidotimod

    go.drugbank.com/drugs/DB11364
    Investigational

    Pidotimod is a synthetic dipeptide with immunomodulatory properties.

    Products: ADIMOD 400 MG./7ML SOLUCION ORAL, ADIMOD 800 SOLUCIÓN
  6. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing

  7. Drug

    Nefazodone

    go.drugbank.com/drugs/DB01149
    ApprovedWithdrawn

    On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. … Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury.

    Synonyms: 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-oneProducts: Lin-nefazodone
  8. Drug

    Pridinol

    go.drugbank.com/drugs/DB13642
    Investigational

    Products: Myopridin 3 mg Tabletten
  9. Target

    Copper

    go.drugbank.com/bio_entities/BE0004825
    TargetHumans

  10. Drug

    Artemether

    go.drugbank.com/drugs/DB06697
    ApprovedInvestigational

    Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

    Mixtures: Riamet 20 mg/120 mg - Tabletten, ARTEMETERO 20 MG + LUMEFANTRINA 120 MG TABLETA